BioNTech and Pfizer Join the mRNA Space in US$425 M Deal
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 8 (Table of Contents)
Published: 22 Aug-2018
DOI: 10.3833/pdr.v2018.i8.2352 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Joining the race for mRNA therapies, BioNTech AG has signed a multi-year deal with Pfizer to develop mRNA vaccine targeting influenza in a deal worth potentially US$425 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS